Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;25(5):685-701.
doi: 10.1007/s10741-019-09860-8.

Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure

Affiliations
Review

Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure

Liza Grosman-Rimon et al. Heart Fail Rev. 2020 Sep.

Abstract

Neurohormones and inflammatory mediators have effects in both the heart and the peripheral vasculature. In patients with heart failure (HF), neurohormonal activation and increased levels of inflammatory mediators promote ventricular remodeling and development of HF, as well as vascular dysfunction and arterial stiffness. These processes may lead to a vicious cycle, whereby arterial stiffness perpetuates further ventricular remodeling leading to exacerbation of symptoms. Although significant advances have been made in the treatment of HF, currently available treatment strategies slow, but do not halt, this cycle. The current treatment for HF patients involves the inhibition of neurohormonal activation, which can reduce morbidity and mortality related to this condition. Beyond benefits associated with neurohormonal blockade, other strategies have focused on inhibition of inflammatory pathways implicated in the pathogenesis of HF. Unfortunately, attempts to target inflammation have not yet been successful to improve prognosis of HF. Further work is required to interrupt key maladaptive mechanisms involved in disease progression.

Keywords: Arterial stiffness; Inflammatory mediators and cardiovascular injury in the setting of heart failure; Neurohormones; Vascular dysfunction; Ventricular remodeling.

PubMed Disclaimer

References

    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239. https://doi.org/10.1016/j.jacc.2013.05.019 - DOI
    1. Krum H, Abraham WT (2009) Heart failure. Lancet 373(9667):941–955. https://doi.org/10.1016/S0140-6736(09)60236-1 - DOI - PubMed
    1. Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348(20):2007–2018. https://doi.org/10.1056/NEJMra021498 - DOI - PubMed
    1. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 35(3):569–582 - PubMed
    1. Mann DL, Bristow MR (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111(21):2837–2849. https://doi.org/10.1161/CIRCULATIONAHA.104.500546 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources